Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Neximmune Inc (NEXI)

Neximmune Inc (NEXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,552
  • Shares Outstanding, K 1,371
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,340 K
  • 60-Month Beta 2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.96
Trade NEXI with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.01 +10.30%
on 04/17/24
5.10 -34.90%
on 04/04/24
-1.73 (-34.26%)
since 04/03/24
3-Month
3.01 +10.30%
on 04/17/24
11.90 -72.10%
on 02/05/24
-9.28 (-73.65%)
since 02/02/24
52-Week
1.25 +165.58%
on 11/24/23
28.69 -88.43%
on 01/30/24
-4.43 (-57.16%)
since 05/03/23

Most Recent Stories

More News
What Makes NexImmune, Inc. (NEXI) a New Buy Stock

NexImmune, Inc. (NEXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NEXI : 3.32 (+6.41%)
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Selexis SA , a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have...

NEXI : 3.32 (+6.41%)
Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More

'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.

INCY : 53.76 (+1.26%)
NVAX : 4.93 (+4.67%)
APLS : 47.46 (-0.06%)
NEXI : 3.32 (+6.41%)
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug

NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.

ALKS : 24.05 (+0.80%)
SRPT : 133.66 (+2.32%)
SGEN : 228.74 (-0.07%)
NEXI : 3.32 (+6.41%)
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

First IND for NexImmune’s AIM nanoparticle platform in solid tumorsIND clearance enables commencement of a clinical trial to evaluate NEXI-003, an...

NEXI : 3.32 (+6.41%)
What Makes NexImmune, Inc. (NEXI) a New Buy Stock

NexImmune, Inc. (NEXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NEXI : 3.32 (+6.41%)
Legend Capital Portfolio: Japan's NO.1 VTuber Operator ANYCOLOR Lists on the Tokyo Stock Exchange

HONG KONG, Jun 9, 2022 - (ACN Newswire) - On June 8th 2022, Legend Capital's portfolio company ANYCOLOR, a leading Virtual YouTuber (VTuber) management company in Japan, was listed on the Tokyo Stock Exchange....

NEXI : 3.32 (+6.41%)
AXNX : 67.28 (+0.25%)
OMIC : 0.4131 (+3.27%)
NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates

Clinical data updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 2H2022Investigational New Drug (IND)...

NEXI : 3.32 (+6.41%)
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

A JDRF funded grant will be used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment...

NEXI : 3.32 (+6.41%)
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors

GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to...

NEXI : 3.32 (+6.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

NexImmune Inc. is a clinical-stage biotechnology company. It engages in developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response that mimics natural biology. NexImmune Inc. is based in GAITHERSBURG, Md.

See More

Key Turning Points

3rd Resistance Point 3.90
2nd Resistance Point 3.69
1st Resistance Point 3.51
Last Price 3.32
1st Support Level 3.12
2nd Support Level 2.91
3rd Support Level 2.73

See More

52-Week High 28.69
Fibonacci 61.8% 18.21
Fibonacci 50% 14.97
Fibonacci 38.2% 11.73
Last Price 3.32
52-Week Low 1.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar